All these findings together seem to indicate that, although therapeutic approach to IBD during COVID-19 should vary according to the characteristics of the patients and IBD severity (43), in general use of all the drugs specifically prescribed for IBD, including TNF antagonist and other biologics, should be continued in case of SARS-CoV-2 infection. This evidence concerns the gene TNF and COVID-19.